Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
In a new study, researchers developed a recombinant bivalent vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses.
In a recent study posted to the bioRxiv* preprint server, researchers in Germany and the United Kingdom investigated the interferon responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant and SARS-CoV-2 Omicron sub-variants BA.1 and BA.5, and their efficacy in protecting cells from influenza A virus super-infection.
A new review attempts to summarize all known about the relationship between viral illness and parkinsonian disorders to facilitate further research.
A new universal flu vaccine protects against diverse variants of both influenza A and B viruses in mice, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.
Epidemics and pandemics have been frightening the human chase again and again. SARS, H1N1, Ebola, and more have exposed their real face in the past, but with every such outbreak.
A combined mRNA vaccine is capable of inducing broad and durable protection against co-infection with SARS-CoV-2 and IAV,
Researchers measured the impact of initial respiratory droplet volume and relative humidity on the environmental stability of respiratory viruses, including influenza A and SARS-CoV-2.
A new study discusses the utility of vitamin C and melatonin as potentially therapeutic and capable of preventing acute lung injury in COVID-19.
A recent study published in Nutrients found that vitamin D is vital for lung protection from viral infection.
A new study reports early prediction of SARS-CoV-2 immune evasion using EVEscape.
As the BA.5 omicron variant continues to spread, health experts are increasingly preparing for a future in which such COVID-19 variants emerge, surge and recede similar to seasonal flu.
A new study has explored the entrapment efficacy of CTB-ACE2 chewing gum against different strains of SARS-CoV-2.
Researchers investigated the effect of influenza A virus pre-exposure and SARS-CoV-2 infection in the elderly population using a 14-month-aged golden Syrian hamsters model.
A recently published study compared monoclonal RBD antibody responses induced by SARS-CoV-2 Beta variant infections to antibodies induced by the ancestral virus in immunologically naive subjects.
A new study describes the immunologic parameters associated with protection from COVID-19.
Vitamin D supplementation reduces inflammation, after H1N1 and SARS-CoV-2 infections in mice.
A recent Swiss study posted to the bioRxiv* preprint server demonstrated that aerosol filters centered on granular protein nanofibrils and iron (Fe) oxyhydroxides nanoparticles could trap virus-containing aerosols.
A new study focused on determining Vitamin D's role in SARS-CoV-2 and H1N1 influenza. In this study, researchers determined the effect of vitamin D supplements on the lung anti-viral response in animal models.
A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged populations, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.
Researchers from the Cancer Epigenetics group led by Dr. Manel Esteller at the Josep Carreras Leukaemia Research Institute and Dr. Aurora Pujol, from the Bellvitge Biomedical Research Institute, have identified an epigenetic signature associated to the development of the Multisystem Inflammatory Syndrome in Children (MIS-C) after a SARS-CoV-2 virus infection.